<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>250</serviceExecutionTime><Trial id="250611"><TitleDisplay>Clinical trial: Comparison of the effects of continuous and short and long-term high interval training on rehabilitation of cardiovascular patients</TitleDisplay><TitleOfficial>Comparison of the effects of continuous and short and long-term high interval training on rehabilitation of cardiovascular patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2015070123002N1</Identifier><Identifier type="Secondary Organisational">IR.BMSU.REC.1394.40</Identifier></Identifiers><Indications><Indication id="626">Heart disease</Indication></Indications><BiomarkerNames><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="153" role="Therapeutic effect marker" type="Biochemical">High-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2089" role="Therapeutic effect marker" type="Physiological">Cardiac Output</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="9438" role="Therapeutic effect marker" type="Physiological">Stroke volume</BiomarkerName><BiomarkerName id="9580" role="Therapeutic effect marker" type="Structural (imaging)">Left ventricle</BiomarkerName><BiomarkerName id="10306" role="Therapeutic effect marker" type="Physiological">Ejection fraction</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>long-term high interval training rehabilitation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>short-term high interval training rehabilitation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1039041" type="Company"><TargetEntity id="5035542352" type="organizationId">Baqiyatallah University Of Medical Sciences</TargetEntity></SourceEntity><SourceEntity id="626" type="ciIndication"><TargetEntity id="10061024" type="MEDDRA"></TargetEntity><TargetEntity id="D006331" type="MeSH"></TargetEntity><TargetEntity id="-1056542095" type="omicsDisease"></TargetEntity><TargetEntity id="217" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1039041">Baqiyatallah University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>90</PatientCountEnrollment><DateStart>2015-11-22T00:00:00Z</DateStart><DateChangeLast>2017-05-11T04:23:49Z</DateChangeLast><DateAdded>2016-01-14T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Baqiyatallah University of Medical Sciences</Affiliation><Email>ghardashi.a@ut.ac.ir</Email><Name>Alireza Ghardashi Afousi</Name><Phone>19395-5487 02182482402 00989137227732</Phone></Contact><Contact type="Public contact"><Affiliation>Baqiyatallah University of Medical Sciences</Affiliation><Email>ghardashi.a@ut.ac.ir</Email><Name>Alireza Ghardashi Afousi</Name><Phone>19395-5487 02182482402 00989137227732</Phone></Contact><Contact type="Scientific contact"><Affiliation>Baqiyatallah University of Medical Sciences</Affiliation><Email>ghardashi.a@ut.ac.ir</Email><Name>Alireza Ghardashi Afousi</Name><Phone>02182482402 00989137227732</Phone></Contact><Contact type="Public contact"><Affiliation>Baqiyatallah University of Medical Sciences</Affiliation><Email>ghardashi.a@ut.ac.ir</Email><Name>Alireza Ghardashi Afousi</Name><Phone>02182482402 00989137227732</Phone></Contact><Contact type="Public contact"><Affiliation>Baqiyatallah University of Medical Sciences</Affiliation><Email>ghardashi.a@ut.ac.ir</Email><Name>Alireza Ghardashi Afousi</Name><Phone>00982182482402 00989137227732</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Sinus rhythm, left ventricular ejection fraction &gt;/= 50% and 4 to 16 week after coronary artery bypass graft surgery&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Coexisting valvular and/or peripheral vascular diseases, frequent atrial or ventricular premature beats, conduction defects, pericarditis, peripheral neuropathy, orthopedic or neurological limitations, cessation of drug use during the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Resting heart rate: polar beat heart rate</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Maximal heart rate: polar beat heart rate</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Ejection fraction: two-dimensional echocardiography</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Cardiac output: two-dimensional echocardiography</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Rate product pressure: two-dimensional echocardiography</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>End-systolic diameter: two-dimensional echocardiography</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>End-diastolic diameter: two-dimensional echocardiography</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Heart rate variabality: cardiac hollter monitoring</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Quality of life: The World Health Organization Quality of Life Questionnaire</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Stroke volume: two-dimensional echocardiography</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Plasma glucose level: enzymatic study</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Serum triglycerides: photometry</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Serum cholesterol: photometry</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Serum LDL: photometry</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Serum HDL: photometry</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure><Measure><Description>Blood pressure: barometer</Description><Timeframe>Before and after 6 week of intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this double-blind study will be investigation and comparison of different exercise training program on rehabilitation of cardiac disease with coronary artery bypass graft operation (CABG).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This trial will divided into four arms:&lt;br/&gt;Intervention group 1: moderate intensity contentious exercise (MICE) consist of 45 min at 70% heart rate reserve, three session per week for 6 week. Warm- up and cool- down for patients at the start and end of each training session is at 50 to 55% heart rate reserve. &lt;br/&gt;Intervention group 2: high intensity interval training-1 consist of: warm up 5 min at 50 to 55% heart rate reserve, and 5 x 4 min at 85 to 90% heart rate reserve and 3 min active period interval at 60 to 70% heart rate reserve, and the end of session of training cool down is 5 min at 50 to 55% heart rate reserve. &lt;br/&gt;Intervention group 3: high intensity interval training-2 consist of: warm up 5 min at 50 to 55% heart rate reserve, and 9 x 2 min at 85 to 90% heart rate reserve and 3 min active period interval at 60 to 70% heart rate reserve, and the end of session of training cool down is 5 min at 50 to 55% heart rate reserve. &lt;br/&gt;Control group: none of the  exercise training program will be given to patients and they will be maintained at daily activities.&lt;br/&gt;After baseline measurement, using the online randomization (http://www.graphpad.com/quickcalcs/index.cfm) subjects randomized and stratified to three groups (high interval intensity training-1, 2 and continuous training)&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Baqiyatallah University of Medical Sciences</Name><Address1>Tehran</Address1><Address2>1435915371</Address2><CountrySubDivision>1435915371</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>bahram pishgoo MD, Mohammad Taghi Holisaz MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="207">Subjects Undergoing /Underwent Major Cardiac Intervention</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2015070123002N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2512"><Endpoint>Assessment of Thrombotic/Thromboembolic Events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2609"><Endpoint>Assessment of Other Cardiovascular Events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2708"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2712"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2713">High-density lipoprotein cholesterol (HDL-C) levels</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2714">Low-density lipoprotein cholesterol (LDL-C) levels</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2719">Serum triglycerides (TG) level </SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2720">Assessment of Total Cholesterol</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2723"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2728"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2733">Assessment of ejection fraction</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2763"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2764">Assessment of blood glucose</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="26218"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="26311">Quality of life(Non-specific)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1163"><Criterion>Subjects with History of/Scheduled for Cardiac Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1174">Subjects with history of/undergoing coronary artery bypass graft surgery (CABG)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1240"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="3895">Subjects with normal left ventricular ejection fraction (LVEF &gt; 50%)</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1638"><Criterion>Subjects with Valvular Heart Diseases</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1646"><Criterion>Subjects with Thromboembolic Events</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1648">Subjects with peripheral vascular disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1668"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1714"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1660">Subjects co-morbid with carditis (pericarditis/myocarditis/endocarditis)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1780"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1787">Musculoskeletal problems /myopathy /muscular dystrophy /myasthenia gravis</SubCriterion><SubCriterion disease="Coronary artery disease" id="5588">Subjects co-morbid with cerebrovascular/CNS disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1820"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2016-02-29T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>3.32 Months</EnrollmentPeriod><EnrollmentRate>27.11 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-01-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-05-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="262930"><TitleDisplay>Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients</TitleDisplay><TitleOfficial>Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02794649</Identifier><Identifier type="Organisational Study">RKSC6416</Identifier><Identifier type="Other">RDCRN 6416</Identifier></Identifiers><Indications><Indication id="1822">Hyperoxaluria</Indication></Indications><BiomarkerNames><BiomarkerName id="213" role="Disease marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="7895" role="Disease marker" type="Physiological">Estimated glomerular filtration rate</BiomarkerName><BiomarkerName id="14648" role="Disease marker" type="Biochemical">Calcium oxalate</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1097059" type="Company"><TargetEntity id="5010217478" type="organizationId">Mayo Clinic</TargetEntity></SourceEntity><SourceEntity id="1099104" type="Company"><TargetEntity id="5028914048" type="organizationId">Department of Veterans Affairs New York Harbor Healthcare System</TargetEntity></SourceEntity><SourceEntity id="20646" type="Company"><TargetEntity id="4295979103" type="organizationId">New York University</TargetEntity></SourceEntity><SourceEntity id="1822" type="ciIndication"><TargetEntity id="E72.53" type="ICD10"></TargetEntity><TargetEntity id="10020703" type="MEDDRA"></TargetEntity><TargetEntity id="D006959" type="MeSH"></TargetEntity><TargetEntity id="-579380868" type="omicsDisease"></TargetEntity><TargetEntity id="336" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1099104">Veterans Affairs New York Harbor Healthcare System</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1097059">Mayo Clinic FLORIDA</Company><Company id="20646">New York University</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Case Control</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2016-06-30T00:00:00Z</DateStart><DateEnd type="estimated">2017-06-30T00:00:00Z</DateEnd><DateChangeLast>2019-02-13T11:50:49Z</DateChangeLast><DateAdded>2016-06-20T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>lama.nazzal@nyumc.org</Email><Extension>3877</Extension><Name>Lama Nazzal, MD</Name><Phone>212-686-7500</Phone></Contact><Contact type="Public contact"><Email>arielle.radin@nyumc.org</Email><Name>Arielle Radin, BA</Name><Phone>646-501-4159</Phone></Contact><Contact type="Public contact"><Affiliation>Mayo Clinic College of Medicine</Affiliation><Email>rarekidneystones@mayo.edu</Email><Name>Julie Olson</Name><Phone>800-270-4637; 507-255-0387|</Phone></Contact><Contact type="Public contact"><Affiliation>Mayo Clinic College of Medicine</Affiliation><Email>rarekidneystones@mayo.edu</Email><Name>Barb Seide</Name><Phone>800-270-4637; 507-255-0387|</Phone></Contact><Contact type="Public contact"><Affiliation>Mayo Clinic College of Medicine</Affiliation><Email>rarekidneystones@mayo.edu</Email><Name>Alicia Meek</Name><Phone>800-270-4637; 507-255-0387|</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Primary hyperoxaluria: patients diagnosed with type I PH by genetic testing and part of the Rare Kidney Stone Consortium (RKSC) primary hyperoxaluria registry&lt;/li&gt;&lt;li&gt;Enteric hyperoxaluria: patients with Roux-en-Y-gastric-bypass&lt;/li&gt;&lt;li&gt;Idiopathic CaOx stone : history of passing or having surgically removed a calcium oxalate kidney stone within five years of recruitment&lt;/li&gt;&lt;li&gt;Healthy participants with no history of kidney or bowel disease&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of kidney or liver transplant&lt;/li&gt;&lt;li&gt;History of antibiotics use within 6 months of recruitment&lt;/li&gt;&lt;li&gt;Have low kidney function (estimated GFR&amp;lt; 50 ml/min/1.73 m2)&lt;/li&gt;&lt;li&gt;Are&amp;lt; 18 or &gt; 60 years of age&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Differences in composition of the fecal microbiome as measured by 16S ribosomal ribonucleic acid (rRNA) sequencing and whole genome shotgun sequencing between the study groups</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Diversity and abundance of operational taxonomic units (OTUs) between different groups of subjects will be tested. Data from shotgun sequencing and degenerate quantitative polymerase chain reactions (qPCRs) will yield comparative expressions of the oxalate metabolism genes between the groups</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study is to characterize the microbiome in four  groups of participants (primary hyperoxaluria type I [PH1],      idiopathic CaOx stone, enteric hyperoxaluria [EH] and healthy participants) by comparing the      number of species and diversity of the microbial populations and pathway for oxalate      metabolism by paralleling the gene expression of enzymes involved in oxalate degradation by      gut bacteria.&lt;/para&gt;&lt;para&gt;Hypothesis: the diversity and number of bacterial populations are different between      individuals with conditions that predispose them to CaOx kidney stones formation and healthy      individuals. The expression of genes involved in oxalate metabolism will be different in      individuals predisposed with these conditions. At the strain level, the investigators expect      a difference in the characteristics of the bacteria Oxalobacter formigenes (OxF) between      healthy participants and participants with primary hyperoxaluria.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The investigators plan to include 15 participants in each group for a total of 60 participants in the study.  The      investigators will include participants in  this study who are at risk of forming kidney      stones. The investigators will include  healthy (non stone forming) participants      (n = 15), participants with a history of calcium oxalate kidney stones      (n = 15), patients with genetic diseases      hyperoxaluria type1 (PH1) (n = 15) and hyperoxaluria (EH) (n = 15) that predispose to form calcium oxalate kidney stones and, patients with fat      malabsorption due to a bariatric surgical procedure (Roux-en Y gastric bypass; RYGB) that      causes enteric hyperoxaluria and calcium oxalate kidney stones. &lt;/para&gt;&lt;para&gt;The investigators will      review the charts of the recruited patients with primary, enteric hyperoxaluria and      idiopathic CaOx stones to collect their clinically obtained 24 h urine parameters. The      investigators will collect data for up to  three years prior to enrollment on kidney function      (Cr, GFR), kidney stone history, kidney stone removal procedures, kidney imaging,      medications, serum electrolytes, 24 h urine parameters and antibiotic use. The investigators will collect two different stool samples within 1 week. Gut microbiome descriptive analysis and comparative expressions of the oxalate metabolism genes  measured by 16S ribosomal ribonucleic acid (rRNA) sequencing, whole genome shotgun sequencing and degenerate quantitative polymerase chain reactions will be observed in this study.&lt;/para&gt;&lt;para&gt;If the participants are seen outside of the study at one of our participating centers, investigators will look at their medical records so that investigators can collect information about their medical history, physical exam and the laboratory tests within three years of the beginning of the study. The stool specimens will be collected at home using kits provided by the medical center and shipped back to our NY Harbor VA Medical Center.&lt;/para&gt;&lt;para&gt;All patients will be asked to:&lt;br/&gt;Fill out a food questionnaire.&lt;br/&gt;Collect two fecal samples.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Mayo Clinic College of Medicine</Name><Address2>Rochester</Address2><CountrySubDivision>Rochester</CountrySubDivision><Contacts></Contacts></Site><Site><Name>New York University</Name><Address2>New York City</Address2><CountrySubDivision>New York City</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Urolithiasis</Disease><PatientSegments><PatientSegment><PatientSegment id="11582">Subjects with Urolithiasis</PatientSegment><SubSegments><SubSegment id="11586">Subjects with calcium stones</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11608">Others</PatientSegment><SubSegments><SubSegment id="11609">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other metabolic disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16409">Others</PatientSegment><SubSegments><SubSegment id="18751">Healthy Subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="18264">Subjects with specific disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02794649</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Urolithiasis" id="22939"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other metabolic disease" id="43018"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other metabolic disease" id="45247"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Urolithiasis" id="45478"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Urolithiasis" id="20717"><Criterion>Subjects with Urolithiasis</Criterion><SubCriteria><SubCriterion disease="Urolithiasis" id="20721">Subjects with calcium stones</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Urolithiasis" id="20733"><Criterion>Subjects with Positve Urological Findings</Criterion><SubCriteria><SubCriterion disease="Urolithiasis" id="20735">Subjects with hyperoxaluria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other metabolic disease" id="32701"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other metabolic disease" id="33470"><Criterion>Subjects with specific disease</Criterion></Inclusion><Inclusion disease="Urolithiasis" id="34664"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Urolithiasis" id="20751">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Urolithiasis" id="17448"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Urolithiasis" id="17449"><Criterion>Subjects with History of/Scheduled for Procedures</Criterion></Exclusion><Exclusion disease="Other metabolic disease" id="24081"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Other metabolic disease" id="24140"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Other metabolic disease" id="25819"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Other metabolic disease" id="26849"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Urolithiasis" id="27676"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Urolithiasis" id="27765"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-05-25T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-06-20T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-01-05T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="272692"><TitleDisplay>Hypofractionated Stereotactic Radiation Therapy of Brain Metastasis: Evaluation of Whole-brain Radiotherapy</TitleDisplay><TitleOfficial>Hypofractionated Stereotactic Radiation Therapy of Brain Metastasis: Evaluation of Whole-brain Radiotherapy</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02913534</Identifier><Identifier type="Organisational Study">ICL_2014_0001</Identifier></Identifiers><Indications><Indication id="3471">Metastatic brain cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Hypofractionated stereotactic radiation therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1049937" type="Company"><TargetEntity id="5001314967" type="organizationId">Institut de Cancerologie de Lorraine</TargetEntity></SourceEntity><SourceEntity id="3471" type="ciIndication"><TargetEntity id="10055093" type="MEDDRA"></TargetEntity><TargetEntity id="585" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1049937">Institut de Cancérologie de la Loire</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2014-03-31T00:00:00Z</DateStart><DateEnd type="actual">2014-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-05-26T05:47:47Z</DateChangeLast><DateAdded>2016-09-26T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Institut de Cancérologie de Lorraine</Affiliation><Name>PHILIPPE ROYER, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with one to three brain metastasis treated in our department with hypofractionated stereotactic radiotherapy (SRT) from March 2008 to February 2013&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;A patient record captured after February 2013&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Overall survival</Description><Timeframe>72 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of  the trial  was to identify in patients with brain metastasis, the predictive factors of overall      survival, survival without local recurrence and survival with progression-free brain      metastasis after complementary whole brain radiotherapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients records would be extracted from the electronic health record system of Institut de Cancérologie de Lorraine and observed for predictive factors of overall survival, survival without local recurrence and survival with progression-free brain metastasis after complementary whole brain radiotherapy.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>Institut de Cancerologie de Lorraine</Name><Address1>Vandoeuvre-les-Nancy</Address1><Address3>54519</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Central nervous system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="12019">Subjects with Advanced CNS Neoplasms</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02913534</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Central nervous system tumor" id="13472"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Central nervous system tumor" id="13477"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></OtherEndpoint><OtherEndpoint disease="Central nervous system tumor" id="44887"><Endpoint>Assessment of Survival</Endpoint><SubEndpoints><SubEndpoint disease="Central nervous system tumor" id="13475">Assessment of Relapse/Recurrence Free Survival</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Central nervous system tumor" id="13056"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13060">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="22411"><Criterion>Subjects with Advanced CNS Neoplasms</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="34416"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Central nervous system tumor" id="10680"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-09-22T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-09-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="273133"><TitleDisplay>Liquid or Solid State of Food on Glycemia, Lipemia and Insulinemia</TitleDisplay><TitleOfficial>Liquid or Solid State of Food on Glycemia, Lipemia and Insulinemia</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02875275</Identifier><Identifier type="Organisational Study">2015/01098</Identifier></Identifiers><Indications><Indication id="175">Hyperlipidemia</Indication><Indication id="1821">Hyperglycemia</Indication><Indication id="441">Hyperinsulinemia</Indication></Indications><BiomarkerNames><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>glucose</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>Porridge</Name></Intervention><Intervention type="InterventionPrimary"><Name>coconut oil</Name></Intervention><Intervention type="InterventionPrimary"><Name>glucose</Name></Intervention><Intervention type="InterventionPrimary"><Name>grass jelly solid</Name></Intervention><Intervention type="InterventionPrimary"><Name>juice</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1085749" type="Company"><TargetEntity id="5046704812" type="organizationId">Clinical Nutrition Research Centre</TargetEntity></SourceEntity><SourceEntity id="175" type="ciIndication"><TargetEntity id="10062060" type="MEDDRA"></TargetEntity><TargetEntity id="D006949" type="MeSH"></TargetEntity><TargetEntity id="-1908196798" type="omicsDisease"></TargetEntity><TargetEntity id="971" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1821" type="ciIndication"><TargetEntity id="10020635" type="MEDDRA"></TargetEntity><TargetEntity id="D006943" type="MeSH"></TargetEntity><TargetEntity id="-1281913538" type="omicsDisease"></TargetEntity><TargetEntity id="510" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="441" type="ciIndication"><TargetEntity id="10060378" type="MEDDRA"></TargetEntity><TargetEntity id="D006946" type="MeSH"></TargetEntity><TargetEntity id="-1990377991" type="omicsDisease"></TargetEntity><TargetEntity id="511" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1085749">Clinical Nutrition Research Centre, Singapore</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>23</PatientCountEnrollment><DateStart>2016-01-12T00:00:00Z</DateStart><DateEnd type="actual">2016-06-27T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:38:22Z</DateChangeLast><DateAdded>2016-09-30T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Clinical Nutrition Research Centre</Affiliation><Name>JeyaKumar Christiani, Phd</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age 21to 40 years&lt;/li&gt;&lt;li&gt;Body Mass Index 18 to 25 kg/m2&lt;/li&gt;&lt;li&gt;Body weight &gt;/= 45 kg&lt;/li&gt;&lt;li&gt;Normal blood pressure (&amp;lt;/= 140/90) and normal fasting blood glucose (&amp;lt; 6.0 mM)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have major chronic disease such as heart disease, cancer or diabetes mellitus, intolerances or allergies to test products&lt;/li&gt;&lt;li&gt;User of insulin or drugs known to affect glucose metabolism and body fat distribution&lt;/li&gt;&lt;li&gt;People with a major medical or surgical event requiring hospitalization within the preceding 3 months&lt;/li&gt;&lt;li&gt;Individuals with the presence of disease or drugs which influence digestion and absorption of nutrients&lt;/li&gt;&lt;li&gt;Current smokers&lt;/li&gt;&lt;li&gt;People who are on any therapeutic diet/drug&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in postprandial blood glucose over 180 min period: blood obtained through fingerprick, analysed using Hemocue analyser. Capillary blood glucose will be assessed at 0, 15, 30, 45, 60, 90, 120, 150, 180 min</Description><Timeframe>180 min</Timeframe></Measure><Measure><Description>Change in postprandial plasma triglyceride over 360 min period: venous blood obtain through cannula, analysed using Cobas analyser. Venous plasma triglyceride will be assessed at 0, 10, 20, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360 min</Description><Timeframe>360 min</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in postprandial plasma insulin over 360 min period: venous blood  obtain through cannula, analysed using Cobas analyser. Venous plasma insulin will be assessed at 0, 10, 20, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360 min</Description><Timeframe>360 min</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study would examine the metabolic effects of three possible test meals (Oleogel) and/or  three      possible test meals (Grass Jelly). The participants would have the option to voluntarily      choose which study part(s) to participate. This study would be evaluated on 40 healthy      Chinese male subjects from the general public over a period of one year.would&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The participants would have the option to voluntarily      choose which study part(s) to participate. This study would be evaluated on 40 healthy      Chinese male subjects from the general public over a period of one year. Treatments would be randomized to receive three different test meals (Oleogel) and/or three different      test meals.&lt;/para&gt;&lt;para&gt;      If the participants take part in this study, the participants would be required to come on three      non-consecutive days and/or five non-consecutive days to evaluate the three different test meals      (Oleogel) and/or three different test meal (Grass jelly) respectively, in random order with a      minimum of 1 week between the test sessions. For each session, the participants would be  required      to come between 8:00 to 9:00 am, with each session lasting approximately 3.5 to 6.5 h.      The participants would have to come following a 10 to 12 h  overnight fast. An indwelling      catheter would be inserted into a vein in the participants' forearm for the remainder of the      test session. The investigators would then take a blood sample from the cannula to measure      baseline values. The investigators would also take the participant's capillary blood via      finger prick to measure blood glucose concentration. After obtaining the baseline blood      samples, the investigator would give the participants the test meal to eat within 10 min      and fill up a 'liking' questionnaire. Following the meal the investigators would take further      blood samples (from the cannula and finger pricks) for the next 10, 20, 30, 45, 60, 90, 120,      150, 180, (treatment 4, 5, 6), 210, 240, 270, 300, 330, 360 min (Treatment 1, 2, 3).&lt;/para&gt;&lt;para&gt;The amount of blood that would be collected at every time point would be about 5 microl droplet      from fingerprick and approximately 5 ml of blood from cannulation, the accumulative amount      per test session would approximately 50 to 80 ml, and the accumulative amount for the entire      study duration would be approximately 240 ml of blood by cannula and finger pricks (Part A)      and 150 ml (Part B). The investigators would also ask the participants to answer a      questionnaire about measurement of hunger and fullness at the same times the blood samples      would be  taken. The appetite-rating questionnaire consists of 100 mm continuous lines anchored at      each end with opposing statements for a question asked. The specific questions asked would      be: how hungry do participant feel?, how full do participant feel?, how strong would be  participants desire to eat?,      how much food do participant think participant can eat? and  did participant have any preoccupation wi th thoughts      of food right now?. Using a pen, participants  would have to make a mark on the line corresponding to      how you feel.&lt;/para&gt;&lt;para&gt;In addition to the VAS scales, the current trial would  collect information on the prospective      portion that participants would like to consume for a range of different foods at different      time points; at every 30 min interval from baseline till the end of each test session.      This computer based task presents a range of foods to participants and asks how much of      this food would you like to consume right now?, allowing the participants to move between a      series of different portions of each food and select the one that the participants would      like to consume at that time based on the participants' feeling of hunger, fullness and      desire to eat. The foods would be deliberately chosen to represent common Singaporean meals,      desserts and snack foods that would be  regularly eaten to relieve hunger in different situations      and the range of portions available would be the same across all foods (20 to 1200 kcals in 20 kcal      steps).&lt;/para&gt;&lt;para&gt;On the evenings before the test sessions, the participants would be expected to come and      collect a standard dinner meal. The participants would be advised not to take part in any      strenuous physical activities for at least 3 days and avoid caffeine and alcohol consumption      the day before the test sessions.&lt;/para&gt;&lt;para&gt;Participants participation in the study would last a maximum of 20.5 h (Part A) and 11.5      h (Part B), include one screening visit lasting around 1 h.&lt;/para&gt;&lt;para&gt;Treatment arms would be:&lt;br/&gt;Arm 1:  glucose solution only.&lt;br/&gt;Arm 2: glucose with grass jelly solution. A 50 g glucose and 3.12 g grass jelly dissolve in water (top up to 200 g).&lt;br/&gt;Arm 3: Glucose with grass jelly (solid). A 50 g glucose and 3.12 g grass jelly and 3.12 g starch dissolve in hot water (top up to 200 g).&lt;br/&gt;Arm 4: porridge and juice only.&lt;br/&gt;Arm 5: porridge and juice with 25 g coconut oil. Add instant porridge with hot water with oil. Consume with commercially available orange juice.&lt;br/&gt;Arm 6: porridge and juice with 25 g coconut oil gel. Add instant porridge with hot water with oleogel. Consume with commercially available orange juice.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Singapore"><Sites><Site><Name>Clinical Nutrition Reseach Centre</Name><Address1>Singapore</Address1><Address3>117599</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02875275</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lipid metabolism disorder" id="23053"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Lipid metabolism disorder" id="23052">Assessment of Triglycerides</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Lipid metabolism disorder" id="23106"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Lipid metabolism disorder" id="23110">Assessment of glucose level</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Insulin resistance" id="23275"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Insulin resistance" id="23276">Assessment of blood glucose</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Insulin resistance" id="23300"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Insulin resistance" id="23309">Assessment of Triglycerides</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hyperinsulinemia" id="24493"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Hyperinsulinemia" id="24494">Assessment of blood glucose</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hyperinsulinemia" id="24515"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Hyperinsulinemia" id="24520">Assessment of Triglycerides</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lipid metabolism disorder" id="23111"><Endpoint>Assessment of Insulin Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hyperinsulinemia" id="24504"><Endpoint>Assessment of Insulin Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin resistance" id="45443"><Endpoint>Assessment of Insulin Levels</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Hyperinsulinemia" id="30978"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Hyperinsulinemia" id="31020">Assessment by Visual Analog Scale (VAS)</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lipid metabolism disorder" id="20053"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lipid metabolism disorder" id="20062">Subjects with no clinically significant abnormality on physical examination, ECG, vitals or labs</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lipid metabolism disorder" id="20061"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Lipid metabolism disorder" id="20148"><Criterion>Subjects with Protocol Specified BMI</Criterion></Inclusion><Inclusion disease="Insulin resistance" id="20225"><Criterion>Subjects with Acceptable Glycemic Levels</Criterion><SubCriteria><SubCriterion disease="Insulin resistance" id="20228">Acceptable fasting glucose</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin resistance" id="20236"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Insulin resistance" id="20272"><Criterion>Subjects with Protocol Specified BMI</Criterion></Inclusion><Inclusion disease="Hyperinsulinemia" id="21229"><Criterion>Subjects with Acceptable Glycemic Levels</Criterion><SubCriteria><SubCriterion disease="Hyperinsulinemia" id="21232">Acceptable fasting glucose</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hyperinsulinemia" id="21239"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Hyperinsulinemia" id="21265"><Criterion>Subjects with Protocol Specified BMI</Criterion></Inclusion><Inclusion disease="Insulin resistance" id="33691"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Insulin resistance" id="20273">Subjects with protocol specified body weights</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hyperinsulinemia" id="33692"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Hyperinsulinemia" id="21266">Subjects with protocol specified body weights</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lipid metabolism disorder" id="33924"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Lipid metabolism disorder" id="20074">Subjects with protocol specified body weights</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin resistance" id="34500"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Insulin resistance" id="20271">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hyperinsulinemia" id="34508"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Hyperinsulinemia" id="21264">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lipid metabolism disorder" id="34509"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Lipid metabolism disorder" id="20055">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lipid metabolism disorder" id="17704"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Lipid metabolism disorder" id="17702">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lipid metabolism disorder" id="17709"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Lipid metabolism disorder" id="17714"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lipid metabolism disorder" id="17734"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Lipid metabolism disorder" id="17735"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Insulin resistance" id="18010"><Criterion>Subjects  with Diabetes Mellitus</Criterion></Exclusion><Exclusion disease="Insulin resistance" id="18016"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Insulin resistance" id="18042"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Insulin resistance" id="18050"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Insulin resistance" id="18051"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Insulin resistance" id="18059"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Insulin resistance" id="18068">Participating in another trial/administration of any investigational drug before wash out period</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hyperinsulinemia" id="18992"><Criterion>Subjects  with Diabetes Mellitus</Criterion></Exclusion><Exclusion disease="Hyperinsulinemia" id="18997"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Hyperinsulinemia" id="19022"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Hyperinsulinemia" id="19030"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Hyperinsulinemia" id="19031"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Hyperinsulinemia" id="19039"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Hyperinsulinemia" id="19048">Participating in another trial/administration of any investigational drug before wash out period</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hyperinsulinemia" id="25099"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Hyperinsulinemia" id="19053">Smokers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin resistance" id="25103"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Insulin resistance" id="18073">Smokers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hyperinsulinemia" id="26895"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Hyperinsulinemia" id="19049">Subjects with history/scheduled for surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin resistance" id="26896"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Insulin resistance" id="18069">Subjects with history/scheduled for surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lipid metabolism disorder" id="26898"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Lipid metabolism disorder" id="17737">Subjects with history/scheduled for surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-06-27T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-08-01T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-09-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-08-04T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="302420"><TitleDisplay>The effect of supportive developmental positions on stress of preterm neonates</TitleDisplay><TitleOfficial>The effect of supportive developmental positions on stress of preterm neonates in neonatal intensive care units in Shiraz University of Medical Sciences hospitals</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2016051025807N1</Identifier><Identifier type="Secondary Organisational">Ir.sums.rec.1394.s285</Identifier></Identifiers><Indications><Indication id="1936">Acute stress disorder</Indication></Indications><BiomarkerNames><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="10169" role="Therapeutic effect marker" type="Physiological">Oxygen saturation</BiomarkerName><BiomarkerName id="10260" role="Therapeutic effect marker" type="Physiological">Respiratory frequency</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>supportive developmental positions</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1057381" type="Company"><TargetEntity id="5035551661" type="organizationId">Shiraz University of Medical Sciences and Health Services</TargetEntity></SourceEntity><SourceEntity id="1936" type="ciIndication"><TargetEntity id="F43.0" type="ICD10"></TargetEntity><TargetEntity id="10001084" type="MEDDRA"></TargetEntity><TargetEntity id="D013315" type="MeSH"></TargetEntity><TargetEntity id="-166634484" type="omicsDisease"></TargetEntity><TargetEntity id="37" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1057381">Shiraz University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Prevention</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2016-02-19T00:00:00Z</DateStart><DateChangeLast>2017-06-28T01:47:17Z</DateChangeLast><DateAdded>2017-06-23T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Shiraz University of Medical Sciences, Fateme (P. B. U. H) School of Nursing and Midwifery</Affiliation><Email>amirzaei@sums.ac.ir</Email><Name>Aazam Nayebmirzaei</Name><Phone>00987136474257</Phone></Contact><Contact type="Scientific contact"><Affiliation>Shiraz University of Medical Sciences</Affiliation><Email>Mitraedraki@yahoo.com</Email><Name>Mitra Edraki</Name><Phone>00987136474257</Phone></Contact><Contact type="Public contact"><Affiliation>Shiraz University of Medical Sciences</Affiliation><Email>amirzaei@sums.ac.ir</Email><Name>Aazam Nayebmirzaei</Name><Phone>00987136474257</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Gestational age of 28 to 36 weeks&lt;/li&gt;&lt;li&gt;Postnatal age of 7 to14 days&lt;/li&gt;&lt;li&gt;Not using sedatives and short- or long-acting skeletal muscle relaxant drugs&lt;/li&gt;&lt;li&gt;Not having substance abuse issues and no sedative drug use by the mother&lt;/li&gt;&lt;li&gt;No major congenital, chromosomal or neurological abnormalities&lt;/li&gt;&lt;li&gt;No need for surgery; no severe growth problems from birth&lt;/li&gt;&lt;li&gt;No evidence of grade II or higher intraventricular hemorrhage&lt;/li&gt;&lt;li&gt;Stability of physiological parameters in the infant&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Symptoms of physiological instability in the infant&lt;/li&gt;&lt;li&gt;Parent's unwillingness to continue cooperating in research&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Heart rate: pulse oximetry</Description><Timeframe>Before and 30 min after putting in supportive developmental position</Timeframe></Measure><Measure><Description>Respiratory rate: observation</Description><Timeframe>Before and 30 min after putting in supportive developmental position</Timeframe></Measure><Measure><Description>Blood oxygen saturation: pulse oximetry</Description><Timeframe>Before and 30 min after putting in supportive developmental position</Timeframe></Measure><Measure><Description>Brazelton sleep score: video camera</Description><Timeframe>Before and 30 min after putting in supportive developmental position</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Study objective is to assess the effect of supportive developmental positions on stress of preterm neonate. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Premature infants who are eligible for the study will be selected by simple sampling. The study will be conducted in two stages. In the first stage before putting the neonate in supportive developmental position physiological parameters and Brazelton sleep score will be measured. In the second stage the same neonates will be placed in the supportive developmental position, physiological parameters and the Brazelton sleep score will be measured. To measure sleep scores in each stages for 10 min the neonates are captured and the films will be interpreted by an analyzer. Finally, the changes in the physiological and sleep sore in two stages compared with each other.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Namazi Hospital</Name><Address1>Shiraz</Address1><Address2>Fars</Address2><CountrySubDivision>Fars</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Aazam Nayebmirzaei</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2016051025807N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><DateEnrollmentEnd type="actual">2016-04-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>2.42 Months</EnrollmentPeriod><EnrollmentRate>12.40 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-06-23T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="325849"><TitleDisplay>The study of clinical significance of prevention and treatment of venous thromboembolism by database of quality control center in Hebei province</TitleDisplay><TitleOfficial>The study of clinical significance of prevention and treatment of venous thromboembolism by database of quality control center in Hebei province</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1800014371</Identifier></Identifiers><Indications><Indication id="325">Thromboembolism</Indication></Indications><BiomarkerNames><BiomarkerName id="183" role="Disease marker" type="Proteomic">D-dimer</BiomarkerName><BiomarkerName id="19664" role="Disease marker" type="Structural (imaging)">Thigh muscle</BiomarkerName><BiomarkerName id="22390" role="Disease marker" type="Anthropomorphic">Calf circumference</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1093628" type="Company"><TargetEntity id="5041752048" type="organizationId">Second Hospital of Hebei Medical University</TargetEntity></SourceEntity><SourceEntity id="325" type="ciIndication"><TargetEntity id="D013923" type="MeSH"></TargetEntity><TargetEntity id="-338631668" type="omicsDisease"></TargetEntity><TargetEntity id="306" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1093628">Second Hospital of Hebei Medical University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Medical procedure</Category><Category>Behavioral intervention</Category></TrialCategories><PatientCountEnrollment>1000</PatientCountEnrollment><DateChangeLast>2018-02-03T22:02:01Z</DateChangeLast><DateAdded>2018-01-18T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Department of Vascular Surgery, Second Hospital of Hebei Medical University</Affiliation><Email>15803210532@163.com</Email><Name>Wei Bi</Name><Phone>+86 15803210532</Phone></Contact><Contact type="Public contact"><Affiliation>Department of Vascular Surgery, Second Hospital of Hebei Medical University</Affiliation><Email>631938357@qq.com</Email><Name>Tao Yuan</Name><Phone>+86 15233658838</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt; Patients diagnosed with venous thromboembolism (VTE)&lt;/li&gt;&lt;li&gt;Life expectancy is greater than one years&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Suspected VTE patients&lt;/li&gt;&lt;li&gt;Life expectancy is less than one years&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The thigh, calf circumferential difference between trouble and healthy side thigh (CM): knee plane &lt;  10 cm and &gt;  10cm</Description><Timeframe>Admission, discharge and follow-up</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>D-Dimer: blood</Description><Timeframe>Admission, preoperative, postoperative and discharge</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objectives of this case series study  are:  &lt;br/&gt; With this platform, the centers in Hebei province could exchang and learn, then reach a consensus. &lt;br/&gt;Formulate the relevant standards for the prevention and treatment of venous thromboembolism  in our province.&lt;br/&gt;Standardize the treatment program of venous thromboembolism, and popularize the key points of new technology and equipment.&lt;br/&gt;Provide theoretical basis for prevention and treatment of venous thromboembolism. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients diagnosed with venous thromboembolism will be observed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Second Hospital of Hebei Medical University</Name><Address1>Shijiazhuang</Address1><Address2>Hebei</Address2><CountrySubDivision>Hebei</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Thrombosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7323">Subjects with Venous Thrombosis</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1800014371</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Thrombosis" id="10336"><Endpoint>Assessment of hospitalization</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Thrombosis" id="10360"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Thrombosis" id="10376">Assessment of anthropometric parameters</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Thrombosis" id="10281"><Endpoint>Assessment of Blood Coagulation</Endpoint><SubEndpoints><SubEndpoint disease="Thrombosis" id="10282">Assessment of D-Dimer levels</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Thrombosis" id="10336"><Endpoint>Assessment of hospitalization</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Thrombosis" id="10360"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint><OtherEndpoint disease="Thrombosis" id="45212"><Endpoint>Clinical Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Thrombosis" id="5942"><Criterion>Subjects with Diagnosis of Thrombosis</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="5944">Subjects with venous thrombosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombosis" id="6040"><Criterion>Subjects with protocol specified life expectancy</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Thrombosis" id="7608"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7612">Subjects with life expectancy of one year or less</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7668"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7683">Subjects at Risk of Developing Thrombosis</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-01-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="352781"><TitleDisplay>Effects of complementary therapies associated with Cardiac Rehabilitation in patients with Chronic Heart Failure</TitleDisplay><TitleOfficial>Effects of Noninvasive Ventilation and Inspiratory Muscle Training Associated with Cardiac Rehabilitation in the Kinetics of Oxygen Consumption in Patients with Chronic Heart Failure</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">U1111-1219-6118</Identifier><Identifier type="Other">RBR-7zccgr</Identifier><Identifier type="Other">65852217.5.0000.5537</Identifier><Identifier type="Other">1,972,470</Identifier></Identifiers><Indications><Indication id="55">Cardiac failure</Indication></Indications><BiomarkerNames><BiomarkerName id="147" role="Therapeutic effect marker" type="Physiological">Six-minute walk distance</BiomarkerName><BiomarkerName id="19714" role="Therapeutic effect marker" type="Physiological">Muscle strength</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>complementary therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>inspiratory muscle training</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>conventional supervised cardiac rehabilitation</Name></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>physiotherapy assistance</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1076120" type="Company"><TargetEntity id="5035438797" type="organizationId">Universidade Federal do Rio Grande do Norte</TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"></TargetEntity><TargetEntity id="10007554" type="MEDDRA"></TargetEntity><TargetEntity id="D006333" type="MeSH"></TargetEntity><TargetEntity id="-1323949873" type="omicsDisease"></TargetEntity><TargetEntity id="237" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1076120">Universidade Federal do Rio Grande do Norte</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>27</PatientCountEnrollment><DateStart>2018-09-03T00:00:00Z</DateStart><DateChangeLast>2018-09-14T02:25:01Z</DateChangeLast><DateAdded>2018-09-10T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Federal University of Rio Grande do Norte</Affiliation><Email>sbruno@ufrnrt.br</Email><Name>Selma Sousa Bruno</Name><Phone>+ 55-084 3215-3135</Phone></Contact><Contact type="Public contact"><Affiliation>Federal University of Rio Grande do Norte</Affiliation><Email>clenia.araujo@terra.com.br</Email><Name>Clênia Oliveira Araújo</Name><Phone>+ 55-084 3215-3135</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients diagnosed with stable chronic heart failure who undergo medical follow-up with a cardiologist and present stable disease suggested by the absence of any change in medication and without previous diagnosis of moderate or severe chronic obstructive pulmonary disease, exercise-induced asthma and previous hospitalization history; in the last 3 months and anginal events in the three months before the study, with left ventricular systolic dysfunction with LVEF less than 40% and New York Heart Association (NYHA) classification in classes II and III&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with musculoskeletal diseases or any other situation that makes it impossible to perform aerobic or resisted exercises. To present worsening of signs and symptoms of HF after starting the proposed rehabilitation program. Present paradoxical breathing or persistent use of accessory breathing muscles or oxygen desaturation during the exercise program&lt;/li&gt;&lt;li&gt;Body mass index (BMI)&amp;lt; 35 kg/m&lt;/li&gt;&lt;li&gt;Any individual with severe, significant arrhythmias or unable to perform the exercise protocol associated with Non-invasive ventilation (NIV) or Respiratory Muscle Training (RMT)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Additional effects of complementary therapies to the cardiac rehabilitation program on the improvement of oxygen consumption, distance traveled during the six-minute walk test with telemetry, and analysis of gases and respiratory muscle strength with the manovacuometer from the observation of a variation of at least 5 % in the pre- and post-intervention measurements</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study is to evaluate the effects of complementary therapies associated with cardiac rehabilitation in patients with chronic heart failure.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study consists of three arms:&lt;/para&gt;&lt;para&gt;Active control arm: patients will undergo conventional supervised cardiac rehabilitation (CR) n = 9, patients will receive physiotherapy assistance 3 times a week for 12 weeks, through an exercise program involving stretching plus pre-warming with walking (10 minutes duration); (20 minutes duration) and resisted exercises will be performed with 50% of the maximal repetition test (1RM) with predominance of the eccentric phase for all groups upper and lower limb muscles. Three sets of 10 repetitions will be performed and each series will have 1 minute of recovery. The positioning and stabilization of each individual will be standardized and the volunteer will be instructed to maintain constant speed and control the breathing by performing the inspiration to rest and exhalation during the movement, avoiding the adverse outcomes of the valsalva maneuver. At each visit, only one muscle group will be exercised, in order to avoid any influence of the cumulative effect of exercises of different muscle groups on the cardiovascular response (20 minutes duration) and active warm-up similar to heating (10 minutes duration).&lt;/para&gt;&lt;para&gt;Experimental (n = 9): patients will be submitted to conventional CR plus a complementary therapy: Non-invasive ventilation (NIV) (n = 9) supervised 3 times per week for 12 weeks (Group 2). Patients will be submitted to the previous exercise protocol to the active control group associated with Non-Invasive Ventilation will use VPAP Auto 25 ResMed System (Resmed USA) operating mode of CPAP continuous positive airway pressure with Mirage nasal mask (Comfort classic, ResMed, USA). CPAP will initially be adjusted to 4 cmH2O and gradually increased from 1 in 1 cmH2O to the maximum of 8 cmH2O and according to the tolerance of each individual for all study participants for 20 minutes, 10 minutes before aerobic exercise and 10 minutes before the resisted exercise.&lt;/para&gt;&lt;para&gt;Experimental comparator (n = 9): patients will undergo conventional cardiac rehabilitation equal to the active control group associated with supervised respiratory muscle training 3 times a week for 12 weeks (Group 3), subjects will be familiar with the Threshold with inspiratory load that will be adjusted weekly up to 40% of the maximum inspiratory pressure. THRESHOLD (Threshold Inspiratory Muscle Trainer, Healthsean Products, Cedar, New Jersey) The supervised inspiratory muscle training will be concomitant to the expiratory, following the protocol performed in the study of Cahalin et al., 2001, the TME will be performed using the inspiratory muscle THRESHOLD in the reverse direction with loading between 5 to 15% of PEMEX 3 times per week with 10 minutes of expiratory training plus 10 min of inspiratory training. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Brazil"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cardiac failure</Disease><PatientSegments><PatientSegment><PatientSegment id="72">Chronic Heart Failure Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="13416">Subjects with NYHA Functional Class	</PatientSegment><SubSegments><SubSegment id="76">Mild /NYHA Functional Class II Heart Failure Subjects</SubSegment><SubSegment id="77">Moderate/NYHA Functional Class III Heart Failure Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1004">WHO ICTRP</Name><Identifiers><Identifier>U1111-1219-6118</Identifier></Identifiers></Registry><Registry><Name id="1020">Brazilian Clinical Trials Registry (ReBec)</Name><Identifiers><Identifier>RBR-7zccgr</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cardiac failure" id="732"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="747">Assessment of oxygen consumption</SubEndpoint><SubEndpoint disease="Cardiac failure" id="753">Six-minute walk test (6MWT)</SubEndpoint><SubEndpoint disease="Cardiac failure" id="758">Walking distance</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cardiac failure" id="1031"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="2149">Muscle Strength and Muscle Mass</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cardiac failure" id="1031"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Cardiac failure" id="1031"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cardiac failure" id="272"><Criterion>Subjects with Chronic Heart Failure</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="290"><Criterion>Subjects with Poor Ejection Fraction</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="447"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="31870"><Criterion>Inclusion of Subjects Based on NYHA Class</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="275">Subjects with heart failure, NYHA class II</SubCriterion><SubCriterion disease="Cardiac failure" id="276">Subjects with heart failure, NYHA class III</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="33478"><Criterion>Subjects with angina</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cardiac failure" id="448"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="679"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="691">Any condition that limit exercise performance/Limitations to exercise testing</SubCriterion><SubCriterion disease="Cardiac failure" id="802">Recent/current hospitalization</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25073"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="670">Muscular dystrophies/skeletal muscle disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27060"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="572">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="28446"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="estimated">2018-11-05T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>2.10 Months</EnrollmentPeriod><EnrollmentRate>12.86 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-09-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="354299"><TitleDisplay>Influence of photodynamic therapy (diode laser) as an adjunct to scaling and root planing on the levels of Gingival Crevicular Fluid (GCF) interleukin-6, 8 and 10 in the treatment of chronic periodontitis</TitleDisplay><TitleOfficial>Effect of Photodynamic Therapy as an Adjunct to Non-Surgical Periodontal Therapy on Gingival Crevicular Fluid (GCF) Interleukin-6, Interleukin-8 and Interleukin-10 Levels in Chronic Periodontitis: A Randomized, Controlled Trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2018/09/015737</Identifier></Identifiers><Indications><Indication id="2360">Periodontitis</Indication></Indications><BiomarkerNames><BiomarkerName id="175" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-10</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="554" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-8</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>periodontal therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>photodynamic therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>photodynamic therapy</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1118626" type="Company"><TargetEntity id="5049406294" type="organizationId">VSPM's Dental College &amp; Research Centre</TargetEntity></SourceEntity><SourceEntity id="2360" type="ciIndication"><TargetEntity id="10034539" type="MEDDRA"></TargetEntity><TargetEntity id="D010518" type="MeSH"></TargetEntity><TargetEntity id="-408856592" type="omicsDisease"></TargetEntity><TargetEntity id="1114" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1118626">VSPM Dental College and Research Centre,nagpur</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2018-09-17T00:00:00Z</DateStart><DateChangeLast>2018-09-26T07:06:47Z</DateChangeLast><DateAdded>2018-09-25T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>VSPM Dental College &amp; Research Centre, Nagpur</Affiliation><Email>vishakhakharkar@gmail.com</Email><Name>Dr Vishakha Kharkar</Name><Phone>9730753400</Phone></Contact><Contact type="Public contact"><Affiliation>VSPM Dental College &amp; Research Centre, Nagpur</Affiliation><Email>drabhaypkolte@gmail.com</Email><Name>Dr Abhay P Kolte</Name><Phone>9011071467</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Gingival Index (GI) &gt; 1&lt;/li&gt;&lt;li&gt;Probing Depth (PD) &gt; 5 mm and Clinical Attachment Loss (CAL) &gt; 3 mm with alveolar bone loss affecting &gt; 30% of the teeth as detected on radiograph at the time of initial diagnosis, based on the classification by American Academy of Periodontology, 1999&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with medical disorders such as cardiovascular or renal disease, etc&lt;/li&gt;&lt;li&gt;Patients with recent history or presence of acute or chronic infection&lt;/li&gt;&lt;li&gt;Individuals with history of tobacco chewing and smoking.&lt;/li&gt;&lt;li&gt;Pregnant and lactating females&lt;/li&gt;&lt;li&gt;Patients with history of periodontal therapy or antibiotic treatment or any other anti-inflammatory medication within previous 6 months&lt;/li&gt;&lt;li&gt;Patients with history of poorly controlled diabetes, liver diseases, malignancy, radiotherapy, or allergy to toluidine blue&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Improvement in GCF levels of Interleukin-6, Interleukin-8, and Interleukin-10 are evaluated in chronic periodontitis patients undergoing Non-Surgical Periodontal therapy along with Photodynamic therapy</Description><Timeframe>3 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Improvement in periodontal status ie, reduction in probing pocket depth and gain in clinical attachment level in chronic periodontitis patients undergoing Non-Surgical Periodontal therapy along with Photodynamic therapy</Description><Timeframe>At 1 and 3 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Study is conducted to evaluate levels of GCF Interleukin-6, Interleukin-8, Interleukin-10 are evaluated in chronic periodontitis patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total of 20 patients with age above 35 years of age including both male and female visiting the Department of Periodontics at VSPM Dental College and research centre Nagpur will be recruited. A brief description of entire procedure will be given to every patient before starting procedure. Written informed consent will be taken from the patients who wish to enrol in the study. Patients will be randomized into one of the two arms:&lt;br/&gt;Arm I: improvement in GCF levels of Interleukin-6, Interleukin-8, and Interleukin-10 will be  evaluated in chronic periodontitis patients undergoing non-surgical periodontal therapy along with photodynamic therapy in 3 months.&lt;br/&gt;Arm II: improvement in periodontal status ie, reduction in probing pocket depth and gain in clinical attachment level in chronic periodontitis patients undergoing non-surgical periodontal therapy along with photodynamic therapy at 1 and 3 months.&lt;/para&gt;&lt;para&gt;For all subjects following periodontal parameters will be recorded: Plaque index, Gingival index, Probing pocket depth, Clinical Attachment loss&lt;/para&gt;&lt;para&gt;The primary outcome will be improvement in GCF levels of Interleukin-6, Interleukin-8, and Interleukin-10 will be  evaluated in chronic periodontitis patients undergoing non-surgical periodontal therapy along with photodynamic therapy in 3 months. Improvement in periodontal status ie, reduction in probing pocket depth and gain in clinical attachment level in chronic periodontitis patients undergoing non-surgical periodontal therapy along with photodynamic therapy at 1 and 3 months.&lt;/para&gt;&lt;para&gt;After clinical examination, GCF samples will be collected GCF levels of Interleukin-6, Interleukin-8, Interleukin-10 levels will be evaluated using Enzyme Linked Immunosorbent Assay kit. Non-surgical periodontal therapy will be performed with or without photodynamic therapy at the site of periodontal pockets at baseline, 1  and 3 months.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>NKP Salve Institute of Medical Sciences</Name><Address1>Nagpur</Address1><Address2>MAHARASHTRA</Address2><Address3>440019</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>VSPM Dental College and Research Centre</Name><Address1>Nagpur</Address1><Address2>MAHARASHTRA</Address2><Address3>440019</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other mouth disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18265">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16570">Subjects with Periodontitis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2018/09/015737</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other mouth disease" id="46441"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Other mouth disease" id="46442">Assessment of cytokines</SubEndpoint><SubEndpoint disease="Other mouth disease" id="46444">Interleukin-6 (IL-6)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other mouth disease" id="43699"><Endpoint>Clinical Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other mouth disease" id="43700">Assessment of probing pocket depth</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other mouth disease" id="43600"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other mouth disease" id="33061"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Other mouth disease" id="33118">Dental patients with probing pocket depth of protocol specified values</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other mouth disease" id="35078"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other mouth disease" id="24056"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other mouth disease" id="24627">Subjects co-morbid with allergic disease/disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other mouth disease" id="24305"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="24629"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="28330"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-09-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="366329"><TitleDisplay>Effect of Macadamia Nut on Cardiometabolic Risk Factors</TitleDisplay><TitleOfficial>Macadamia Nut Effects on Adiposity and Cardiometabolic Risk Factors</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03801837</Identifier><Identifier type="Organisational Study">2170062</Identifier><Identifier type="Trial Acronym">MAC</Identifier></Identifiers><Indications><Indication id="57">Cardiovascular disease</Indication></Indications><BiomarkerNames><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="7586" role="Therapeutic effect marker" type="Anthropomorphic">Body fat percentage</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>macadamia nut diet</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>control diet</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="21237" type="Company"><TargetEntity id="5021678902" type="organizationId">Loma Linda University</TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"></TargetEntity><TargetEntity id="D002318" type="MeSH"></TargetEntity><TargetEntity id="-1500764314" type="omicsDisease"></TargetEntity><TargetEntity id="182" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21237">Loma Linda University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Prevention</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2019-03-31T00:00:00Z</DateStart><DateEnd type="estimated">2021-03-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-17T12:40:36Z</DateChangeLast><DateAdded>2019-01-16T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>akaur1@llu.edu</Email><Extension>47169</Extension><Name>Amandeep Kaur, MPH</Name><Phone>909-558-4300</Phone></Contact><Contact type="Scientific contact"><Affiliation>Loma Linda University</Affiliation><Name>Joan Sabate, DrPH</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy men and post-menopausal women&lt;/li&gt;&lt;li&gt;Overweight (BMI 25 to 34)&lt;/li&gt;&lt;li&gt;Waist circumference &gt;/=    88.9 cm for women and &gt;/= 101.6 cm for men&lt;/li&gt;&lt;li&gt;At least one of the following within the past year:&lt;ul&gt;&lt;li&gt;Plasma triglycerides &gt;/= 150 mg/dl&lt;/li&gt;&lt;li&gt;Blood pressure &gt;/= 130/85 mmHg&lt;/li&gt;&lt;li&gt;Fasting glucose &gt;/= 100 mg/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Nut allergy, any&lt;/li&gt;&lt;li&gt;Significant chronic disease including diabetes,congestive heart failure,renal failure,cirrhosis, or autoimmune disease&lt;/li&gt;&lt;li&gt;Medications affecting lipid or glucose metabolism, immune modulators, or antibiotics in the last 6 months&lt;/li&gt;&lt;li&gt;Mega-doses of lipid-lowering dietary supplements in the last 6 months&lt;/li&gt;&lt;li&gt;Cancer in the last   ten years (with the exception on non-melanoma skin cancer)&lt;/li&gt;&lt;li&gt;Pregnancy or lactation&lt;/li&gt;&lt;li&gt;Weight change of&amp;gt; 10% of body weight in the last 3 months&lt;/li&gt;&lt;li&gt;Excessive caffeine intake (&amp;gt; 2 cups/day) or alcohol intake (&amp;gt; 1 drink/day for women, &amp;gt; 2 drinks/day for men)&lt;/li&gt;&lt;li&gt;Tobacco use&lt;/li&gt;&lt;li&gt;Claustrophobia (may affect BOD POD testing)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in body weight: the objective of this measure is to see if eating macadamia nuts could reduce body weight. An In body machine will be used to identify this by measuring the weight of the participants at the baseline and at the end of each diet phase. The weight will be measured in kg</Description><Timeframe>Baseline to 5 months</Timeframe></Measure><Measure><Description>Change in body adiposity: the objective of this measure is to see if eating macadamia nuts could reduce percentage body fat. Air Displacement Plethysmography will be used to determine any change in body percentage fat at the baseline and end of each diet phase</Description><Timeframe>Baseline to 5 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study will test the effects of macadamia nuts on adiposity, traditional and emergent risk factorsof cardiometabolic disease in adult men and women.The purpose of this study is to investigate the effects of Macadamia nuts on body weight, adiposity, oxidative stress, glucose, insulin and lipid levels.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This  will be randomized, crossover study that will include two study diets (Macadamia nut diet and control diet) with a wash out period of 4 weeks in between. Subjects (n = 40) will be selected and randomized into either of the two phases. During the Macadamia nut diet phase subjects will  have their habitual diet supplemented with appropriate portion of Macadamia nuts (15% of daily calories or 30 to 45 g based on kcal requirement of the individual, instructions will be provided on how to incorporate nuts into the diet. this phase will last for 8 weeks. During the control diet phase, subjects will continue with their normal diet and abstain from eating nuts. Subjects will be tested for various outcomes at baseline and twice at the end of each phase. The intervention will last for 5 months in total.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Loma Linda University School of Public Health</Name><Address1>Loma Linda</Address1><Address2>California</Address2><Address3>92350</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7733">Overweight (pre-obese) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7752">Others</PatientSegment><SubSegments><SubSegment id="18680">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other cardiovascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16529">Others</PatientSegment><SubSegments><SubSegment id="14550">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03801837</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20392"><Endpoint>Assessment of fat</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20399">Assessment of abdominal fat/obesity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20400">Assessment of Body Weight</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Other cardiovascular disease" id="48045"><Endpoint>Anthropometric Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Obesity" id="20413"><Endpoint>Assessment of Insulin Levels</Endpoint></OtherEndpoint><OtherEndpoint disease="Obesity" id="20432"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20433">Assessment of blood glucose</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Obesity" id="20446"><Endpoint>Assessment of lipid profiles</Endpoint></OtherEndpoint><OtherEndpoint disease="Obesity" id="20524"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></OtherEndpoint><OtherEndpoint disease="Obesity" id="20597"><Endpoint>Assessment of Cardiovascular Risk Factors</Endpoint></OtherEndpoint><OtherEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20400">Assessment of Body Weight</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Other cardiovascular disease" id="42989"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19672"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19673">Subjects with elevated abdominal circumference</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19705"><Criterion>Subjects with High Fasting Glucose</Criterion></Inclusion><Inclusion disease="Obesity" id="19787"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22428">Overweight Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other cardiovascular disease" id="32809"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other cardiovascular disease" id="32945"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Obesity" id="33733"><Criterion>Subjects with Protocol Specified Menstrual Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19750">Postmenopausal women</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other cardiovascular disease" id="34479"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Inclusion><Inclusion disease="Obesity" id="34498"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19746">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other cardiovascular disease" id="34636"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="32811">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="35298"><Criterion>Subjects with Abnormal Laboratory Parameters</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15295"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15380">Subjects co-morbid with claustrophobia</SubCriterion><SubCriterion disease="Obesity" id="15401">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15299"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Obesity" id="15310"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Obesity" id="15311"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15312">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15315"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15322">Subjects co-morbid with heart failure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15325"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15331">Subjects with neoplasm/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15328"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15345">Subjects on vitamin/dietary supplements</SubCriterion><SubCriterion disease="Obesity" id="15349">Subjects on lipid modifying agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15354"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15365">Hypersensitivity/Contraindication to dietary supplements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15364"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="23962"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="24099"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="24585"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="24955"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Obesity" id="24974"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15397">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other cardiovascular disease" id="25146"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="24456">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other cardiovascular disease" id="26092"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="27233"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Obesity" id="28500"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15408">Weight loss/gain with in protocol specified period</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other cardiovascular disease" id="28503"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="29170"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-01-07T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="366478"><TitleDisplay>The Evaluation of Fractional Flow Reserve and D SPECT for the Intervention of Chronic Total Occlusion</TitleDisplay><TitleOfficial>The Evaluation of Fractional Flow Reserve and D SPECT for the Intervention of Chronic Total Occlusion</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03803020</Identifier><Identifier type="Organisational Study">SHDC12018X05</Identifier></Identifiers><Indications><Indication id="1640">Occlusive coronary artery disease</Indication></Indications><BiomarkerNames><BiomarkerName id="10487" role="Disease marker" type="Physiological">Fractional Flow Reserve</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>D Single-Photon Emission Computed Tomography (SPECT)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>elective percutaneous coronary intervention (PCI)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1074642" type="Company"><TargetEntity id="5037940671" type="organizationId">Zhongshan Hospital Fudan University</TargetEntity></SourceEntity><SourceEntity id="1640" type="ciIndication"><TargetEntity id="10011086" type="MEDDRA"></TargetEntity><TargetEntity id="227" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1074642">Shanghai Zhongshan Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>150</PatientCountEnrollment><DateStart>2019-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2021-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-21T06:36:10Z</DateChangeLast><DateAdded>2019-01-18T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>chang.shufu@zs-hospital.sh.cn</Email><Name>Shufu chang,</Name><Phone>+8618616881731</Phone></Contact><Contact type="Scientific contact"><Affiliation>Department of Cardiology, Zhongshan Hospital</Affiliation><Name>Jianying Ma</Name></Contact><Contact type="Public contact"><Email>chang.shufu@zs-hospital.sh.cn</Email><Name>Shufu chang</Name><Phone>+18616881731</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;gt; 18 years old&lt;/li&gt;&lt;li&gt;Single CTO lesions, or other stenosis have been PCI treated for&amp;lt;  1 months&lt;/li&gt;&lt;li&gt;The diameter of target vessel &gt;/= 2.5 mm&lt;/li&gt;&lt;li&gt;Stable angina pectoris, or myocardial ischemia in the area of CTO lesions&lt;/li&gt;&lt;li&gt;The patients agree to this research plan and sign the consent form, and complete the follow-up&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Acute myocardial infarction in one month&lt;/li&gt;&lt;li&gt;In addition to the area of CTO lesions, there are serious untreated coronary lesions&lt;/li&gt;&lt;li&gt;Bridge vascular CTO lesions&lt;/li&gt;&lt;li&gt;Untreated coronary artery or cardiac surgery due to interventional complications, or intraoperative death&lt;/li&gt;&lt;li&gt;Acute decompensated heart failure&lt;/li&gt;&lt;li&gt;Allergies to contrast or radionuclide tracers&lt;/li&gt;&lt;li&gt;Patients with planned pregnancies or lactation or one years after intervention&lt;/li&gt;&lt;li&gt;Malignant neoplasms or life expectancy of&amp;lt; one years&lt;/li&gt;&lt;li&gt;Patients plan of surgery&lt;/li&gt;&lt;li&gt;Patients cannot tolerate double antiplatelet therapy for at least 12 months&lt;/li&gt;&lt;li&gt;Any condition that does not fit coronary intervention or is a drug-eluting stent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Score of seattle angina questionnaire: the result of seattle angina questionnaire</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Score of self-rating anxiety scale: result of socre of self-rating anxiety scale</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Score of EuroQol five dimensions questionnaire: result of EuroQol five dimensions questionnaire</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Composite of cardiac death, target vessel myocardial infarction and target lesion revascularization record in follow-up: composite of cardiac death, target vessel myocardial infarction and target lesion revascularization record in follow-up</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>The success rate of percutaneous coronary intervention: the success rate of percutaneous coronary intervention</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Rate of cardiac death rate: rate of cardiac death rate in one year recorded in follow-up</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Rate of recurrent myocardial infarction rate: rate of recurrent myocardial infarction rate in one year recorded in follow-up</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Rate of target vessel revascularization rate: rate of target vessel revascularization rate in one year recorded in follow-up</Description><Timeframe>One year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to assess the functional result of coronary chronic total occlusions (CTO)      percutaneous coronary intervention (PCI) by measuring fractional flow reserve (FFR) and D Single-Photon Emission Computed Tomography (SPECT) before and immediately post-CTO PCI and at short-term      follow-up.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with symptomatic stable angina of single coronary chronic total occlusion without other coronary artery stenosis scheduled for elective PCI. Fractional flow reserve and SPECT detection before and after intervention will be observed and analyzed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Zhongshan Hospital</Name><Address1>Shanghai</Address1><Address2>Shanghai</Address2><Address3>200032</Address3><CountrySubDivision>Shanghai</CountrySubDivision><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>jbge@zs-hospital.sh.cn</Email><Name>junbo Ge</Name><Phone>+86-21-64041990</Phone></Contact><Contact type="Facility contact"><Email>ma.jianying@zs-hospital.sh.cn</Email><Name>jianying Ma</Name><Phone>+8618616881653</Phone></Contact><Contact type="Facility investigator"><Name>Shufu Chang</Name></Contact><Contact type="Facility investigator"><Name>Rende Xu</Name></Contact><Contact type="Facility investigator"><Name>Qing Qin</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="182">Subjects with Angina</PatientSegment><SubSegments><SubSegment id="188">Subjects with Stable Angina</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="201">Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="243">Subjects with Abnormal Angiographic Findings</PatientSegment><SubSegments><SubSegment id="251">Stenosis/Narrowing of vessel</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="368">Subjects with Myocardial Ischemia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03803020</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2491"><Endpoint>Assessment of Cardiovascular Events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2571"><Endpoint>Assessment of Vascular Indices or Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2703">Assessment of target lesion revascularization (TLR)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2621"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2622">Cardiovascular mortality</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2666"><Endpoint>Assessment of Procedure and Procedure Related Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2686">Procedural success</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2688">PTCA [percutaneous coronary angioplasty] (with or without stenting)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2800"><Endpoint>Assessment of Neuropsychological Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="26218"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="26220">Assessment of European Quality of Life Questionnaire (EuroQol: EQ-5D)</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="26228">Assessment by Seattle Angina Questionnaire (SAQ)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Coronary artery disease" id="2491"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2499">Recurrent MI</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2571"><Endpoint>Assessment of Vascular Indices or Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2704">Target vessel revascularization (TVR)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2621"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2622">Cardiovascular mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Coronary artery disease" id="2571"><Endpoint>Assessment of Vascular Indices or Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2672">Fractional flow reserve (FFR)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Coronary artery disease" id="2803"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="35242">Nuclear imaging (SPECT) findings</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1068"><Criterion>Subjects with Coronary Artery Disease (CAD)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1069">Subejcts with coronary artery stenosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1085"><Criterion>Subjects with angina</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1091">Subjects with stable angina / angina pectoris / exertional angina</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1169"><Criterion>Subjects with History of /Scheduled for Coronary Revascularization Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1171">PTCA (percutaneous transluminal coronary angioplasty)/Stent placement</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1240"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Coronary artery disease" id="33705"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Coronary artery disease" id="34361"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1249">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="34812"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1252">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1602"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1651"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1662">Subjects co-morbid with congestive heart failure (Killip class II-IV/NYHA Class II-IV)/Failure of the right ventricle/Decompensated heart failure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="23442"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1941">Small life expectancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="24889"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1884">Anticoagulation /antiplatelet /anti-thrombotic</SubCriterion><SubCriterion disease="Coronary artery disease" id="1896">Subjects with Hypersensitivity/contraindications to contrast media/agent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="25741"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1939">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="25865"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="5589">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26088"><Criterion>Subjects with history of cardiac surgery/intervention</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="26090"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2021-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-12-28T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>